Novartis Ag (NVSEF) Liabilities from Discontinued Operations (2013 - 2023)

Novartis Ag's (NVSEF) quarterly Liabilities from Discontinued Operations came in at 34000000.0 in Q2 2023, up 9.68% quarter-over-quarter from 31000000.0 in Q4 2019.

Novartis Ag (NVSEF) Liabilities from Discontinued Operations (2013 - 2023) Analysis & Trends

Novartis Ag has disclosed Liabilities from Discontinued Operations across 4 years of filings, most recently posting 34000000.0 for Q2 2023.

  • Liabilities from Discontinued Operations for Q2 2023 came in at 34000000.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2023 was 34000000.0 (changed N/A YoY), and the FY2019 annual result was 31000000.0, down 39.22% from the prior year.
  • Liabilities from Discontinued Operations came in at 34000000.0 for Q2 2023 at Novartis Ag, up from 31000000.0 in the prior quarter.
  • In the past five years, Liabilities from Discontinued Operations ranged from a high of 50000000.0 in Q2 2019 to a low of 24000000.0 in Q3 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag - - -

Historic Data

Download Data
DateValue
Jun 30, 2023 34.00 Mn
Jun 30, 2023 34.00 Mn
Dec 31, 2019 31.00 Mn
Dec 31, 2019 31.00 Mn
Sep 30, 2019 24.00 Mn
Sep 30, 2019 24.00 Mn
Jun 30, 2019 50.00 Mn
Jun 30, 2019 50.00 Mn
Mar 31, 2019 41.00 Mn
Mar 31, 2019 41.00 Mn
Dec 31, 2018 51.00 Mn
Dec 31, 2018 51.00 Mn
Sep 30, 2018 76.00 Mn
Sep 30, 2018 76.00 Mn
Dec 31, 2013 50.00
Dec 31, 2013 50.00